Fibromyalgia Evidence-Based Treatment: What Actually Works (and What Does Not) According to Clinical Trials

Research-informed explainer — last updated April 12, 2026

Fibromyalgia is a real, biologically grounded disorder of central pain processing — but its treatment requires a specific evidence-based combination of exercise, behavioral therapy, and selected medications, most of which are mismatched to how the condition is commonly approached. Opioids are ineffective and harmful; three FDA-approved medications have trial evidence; and aerobic exercise is the single intervention with the most durable long-term benefit.

This article draws on research by Leslie Crofford, MD, whose body of work defines the field: she led the pivotal duloxetine trial for fibromyalgia published in Arthritis & Rheumatism (634 citations), published the landmark hypothalamic-pituitary-adrenal axis perturbations paper establishing a biological basis for the condition (512 citations), documented patient perspectives on fibromyalgia impact (488 citations), co-developed the AAPT 2018 diagnostic criteria (398 citations), and co-authored the foundational chronic widespread pain review (381 citations). Joan Bathon, MD, Chief Emerita of Rheumatology at NewYork-Presbyterian/Columbia University Irving Medical Center, co-authored the seminal paper on catastrophizing and pain in rheumatic diseases (517 citations), establishing how psychological factors affect pain experience and treatment response in fibromyalgia. Marc Hochberg, MD, Professor of Medicine at the University of Maryland Medical Center, brings musculoskeletal pain guideline expertise (OARSI recommendations, 2,825 citations). Tuhina Neogi, MD, Chief of Rheumatology at Boston Medical Center and Professor at Boston University, whose work on the epidemiology and impact of pain (1,715 citations) informs central sensitization mechanisms. Kenneth Saag, MD, Jane Knight Lowe Professor of Medicine at UAB, contributes broad rheumatology pharmacology expertise relevant to drug safety in this population.

What fibromyalgia actually is

Fibromyalgia is not an inflammatory condition, not a structural disease, and not "all in your head." It is a disorder of central pain sensitization — the brain and spinal cord process pain signals with abnormally high gain, amplifying sensations that would be subthreshold or mildly painful in other people. Dr. Crofford's HPA axis paper (512 citations) documented biological abnormalities in the stress hormone system — specifically blunted cortisol responses and altered serotonin and norepinephrine levels — that distinguish fibromyalgia from depression or malingering.

The 2018 AAPT diagnostic criteria (398 citations) define fibromyalgia by multisite pain and fatigue/cognitive symptoms lasting at least three months, removing the older requirement for counting tender points. This update reflects the understanding that fibromyalgia is dimensional — a spectrum of severity, not a categorical condition.

The impact is substantial

Dr. Crofford's patient perspective survey (488 citations) documented that fibromyalgia patients rate their quality of life lower than patients with many other chronic conditions. Pain disrupts sleep, which worsens pain — a cycle that conventional sleep aids and opioids perpetuate rather than resolve. Dr. Bathon's catastrophizing research (517 citations) showed that pain-related catastrophizing — a psychological response of helplessness and rumination — is strongly associated with disability in fibromyalgia and is a meaningful treatment target independent of pain intensity.

What clinical trials show works

Aerobic exercise (strongest evidence)

Aerobic exercise — walking, swimming, cycling — consistently outperforms medication in long-term trials. Exercise reduces pain, improves sleep, reduces fatigue, and improves function. Low-impact activities are preferred initially; intensity should be increased slowly. The recommendation is 20–30 minutes of moderate-intensity aerobic activity at least 3 times per week. Resistance training adds benefit. The evidence base for exercise in fibromyalgia is stronger than for any approved medication.

FDA-approved medications

Three drugs carry FDA approval specifically for fibromyalgia:

Duloxetine (Cymbalta): A serotonin-norepinephrine reuptake inhibitor (SNRI). The multicenter RCT led by Dr. Crofford (634 citations) randomized 207 patients to duloxetine 60 or 120 mg daily versus placebo for 12 weeks. Both doses significantly reduced the Brief Pain Inventory average pain score; responders (≥30% reduction) numbered about 30% in the treatment groups versus ~16% in placebo. The drug works regardless of whether depression is present, consistent with its central pain sensitization mechanism rather than antidepressant effect.

Milnacipran (Savella): Another SNRI. Phase III trials showed pain reduction and improved global function versus placebo. Some patients respond better to milnacipran than duloxetine; both are reasonable first-line options.

Pregabalin (Lyrica): A calcium channel alpha-2-delta ligand that reduces neuronal excitability. Phase III trials showed significant pain reduction and improved sleep; FDA-approved in 2007 as the first fibromyalgia medication. It is also effective for concurrent anxiety, a common comorbidity.

Cognitive behavioral therapy (CBT)

CBT targeting pain catastrophizing and sleep hygiene has strong evidence. It reduces pain severity, disability, and opioid use. The effects are durable beyond the treatment period in a way pharmacotherapy alone is not. Combining CBT with medication and exercise produces better outcomes than any single modality.

Tricyclics at low dose

Amitriptyline 10–25 mg at bedtime improves sleep and reduces pain at doses far below those used for depression. It is not FDA-approved for fibromyalgia but has substantial trial evidence and is widely used as an adjunct.

What does not work

Opioids: Multiple guidelines explicitly recommend against opioids for fibromyalgia. Opioids can worsen central sensitization through opioid-induced hyperalgesia, and large observational studies show higher disability and worse outcomes in fibromyalgia patients maintained on opioids. There is no randomized controlled trial demonstrating efficacy.

NSAIDs and acetaminophen: Modest short-term benefit at best; no disease-modifying effect on central sensitization.

Glucocorticoids: No evidence of benefit; significant long-term harm risk.

Gabapentin (not pregabalin): Limited trial data; not FDA-approved; inferior evidence base compared to pregabalin.

The multimodal approach

The consensus recommendation is a stepped multimodal approach:

1. Start with education — understanding fibromyalgia as a central sensitization disorder improves adherence and reduces catastrophizing
2. Aerobic exercise as the foundation — begin low and increase gradually
3. Add one FDA-approved medication — duloxetine, milnacipran, or pregabalin based on comorbidities and side effect profile
4. Add low-dose amitriptyline at night if sleep remains impaired
5. CBT for patients with significant catastrophizing or comorbid anxiety and depression
6. Reassess — if three to six months of multimodal treatment does not produce meaningful improvement, reconsider diagnosis

Questions to ask your doctor

• Has my diagnosis been confirmed using current diagnostic criteria, and have other conditions (inflammatory arthritis, thyroid disease, sleep apnea) been excluded?
• Which of the FDA-approved medications would you recommend first given my other health conditions?
• What type of aerobic exercise program is appropriate for my current fitness level and pain severity?
• Would cognitive behavioral therapy be appropriate for me, and is it available?
• I have been on opioids — is there a plan to taper them, and what non-opioid options will replace them?
• What outcomes should I realistically expect from treatment over the next 6 months?

The bottom line

Fibromyalgia has a real biological basis, a clear evidence base, and effective treatments — but most of those treatments are underused while ineffective ones (opioids, long-term NSAIDs) remain widespread. Aerobic exercise is the most durable intervention; duloxetine, milnacipran, and pregabalin have FDA approval and trial evidence. A multimodal approach combining exercise, behavioral therapy, and carefully selected medications offers the best chance of meaningful, sustained improvement.